Table 4.

Transdifferentiation of RFP+CoRL to different glomerular cell types in the IGC

Data from Intra-IGCPodocytesPECsMesangial Cells
Total No. of RFP+Synpo+ CoRL in Glomeruli in Entire Kidney SectionRFP+Synpo+/RFP+CoRL (Transdifferentiation Rate to a Podocyte Phenotype), %Total No. of RFP+PAX8+ CoRL in Glomeruli in Entire Kidney SectionRFP+PAX8+/RFP+ CoRL (Transdifferentiation Rate to a PEC Phenotype), %Total No. of RFP+α8I+ CoRL in Glomeruli in Entire Kidney SectionRFP+α8I+/RFP+ CoRL (Transdifferentiation Rate to a Mesangial Cell Phenotype), %
Baseline (no FSGS)
 H2O alone000000
FSGS day 28
 FSGS+H2O2.6±2.510.05±10.220000
(P=0.08 versus H2O)(P>0.05 versus H2O)
 FSGS+hydralazine2.0±2.611.54±11.3900.33±0.5800
(P=0.7 versus FSGS H2O)(P=0.9 versus FSGS H2O)(P=0.21 versus FSGS H20)
FSGS+enalapril21±3.3a17.29±8.524.8±2.39b3.24±0.8494.6±61.8c58.49±7.56
(P<0.001 versus FSGS hydralazine)(P=0.4 versus FSGS hydralazine)(P=0.02 versus FSGS hydralazine)(P=0.001 versus FSGS hydralazine)(P<0.04 versus FSGS hydralazine)(P<0.001 versus FSGS hydralazine)
FSGS+losartan10.2±3.7d11.59±5.941.6±1.141.7±1.0935.2±16.5739.4±5.38
(P=0.01 versus FSGS hydralazine)(P=0.8 versus FSGS hydralazine)(P=0.13 versus FSGS hydralazine)(P=0.04 versus FSGS hydralazine)(P=0.01 versus FSGS hydralazine)(P<0.001 versus FSGS hydralazine)
  • a In FSGS, the number of RFP+Synpo+CoRL was 10.5-fold higher in the enalapril-treated group compared with hydralazine treatment.

  • b In FSGS, the number of RFP+PAX8+CoRL was 4.8-fold higher in the enalapril-treated group compared with hydralazine treatment.

  • c In FSGS, the number of RFP+a8I+CoRL was 94.6-fold higher in the enalapril-treated group compared with hydralazine treatment.

  • d In FSGS, the number of RFP+Synpo+CoRL was 5.1-fold higher in the losartan-treated group compared with hydralazine treatment.